权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Parkinson's Disease Neuroprotection Clinical Trial

帕金森病神经保护临床试验

基本信息

批准号：
8204822
负责人：
MICHAEL Jeffrey AMINOFF
金额：
$ 8.11万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-09-15 至 2012-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8204822
关键词：
Achievement Ally Alzheimer&apos s Disease Animal Model Animals Anti-Inflammatory Agents Anti-inflammatory Award Botox California Caring Climate Clinic Clinical Clinical Research Clinical Services Clinical Trials Collaborations Community Outreach Dentistry Diagnosis Diagnostic Discipline of Nursing Disease Dopamine Dystonia Education Educational process of instructing Family Foundations Funding General Hospitals Genetic Goals Grant Head Health Health Sciences Health Services Human Human Resources Hyperactive behavior Immunologics Industry Inflammatory International Mediating Medical Staff Medical center Medicine Memory Disorders Microglia Mission Movement Disorders National Institute of Neurological Disorders and Stroke Neurodegenerative Disorders Neurologic Dysfunctions Neurology Neuroprotective Agents Neurosciences Pain Pain Clinics Parkinson Disease Parkinsonian Disorders Pathogenesis Patient Care Patients Pharmaceutical Preparations Pharmacy facility Physicians Population Process Protocols documentation Recording of previous events Research Research Personnel Research Training San Francisco Schools Scientist Sclerosis Services Social Sciences Source Specific qualifier value Students Testing Training Training and Education United States United States National Institutes of Health Universities Veterans base clinical care cytokine dopaminergic neuron experience medical schools medical specialties member neuroprotection novel population based prospective response tertiary care treatment trial uptake

项目摘要

Parkinson's disease (PD) is the second most common neurodegenerative disorder. While a number symptomatic therapies have been developed, no treatment has been identified that halts or slows this progressive disorder. For a number of reasons, we believe that it is appropriate to begin a prospective clinical trial of one or more of the more promising agents to determine whether they offer benefit. The aim of this application is to participate as a clinical center in a collaborative study of neuroprotective agents. The agents and protocol will be specified by NINDS. UCSF has a long history in providing subspecialty care for subjects with PD. The UCSF Parkinson's Disease Clinic & Research Center (PDCRC) has been involved in a number of clinical trials to elucidate the neurologic dysfunction underlying PD as well as testing a variety of novel treatments for PD. This research has included a number of industry sponsored treatment trials for subjects with early to advanced PD. A large diverse, local population provides a reliable source of motivated subjects for clinical research. The experience of the UCSF PDCRC in evaluating, selecting and following subjects with PD make it an ideal candidate for a multicenter, prospective trial of a potential neuroprotectant therapy. The ideal neuroprotective treatment should be effective, inexpensive, well tolerated, safe, easy to administer, and have few interactions with common medications. A number of studies over the last decade in humans and experimental animals have demonstrated a local immunologic response mediated by microglia and a number of inflammatory cytokines. Moreover, several animal models of PD have demonstrated that anti-inflammatory medications can interfere with the local immunologic response, and that they may preserve function of dopaminergic neurons. Although emerging understanding of the pathogenesis of PD may provide an alternative candidate for a neuroprotectant therapy, we propose that an anti-inflammatory medication would be a rational and practical candidate for the Parkinson's disease Neuroprotection Trial.

帕金森病（PD）是第二常见的神经退行性疾病。虽然有一些症状